Cancer drug sorafenib could help save Insulin-Making cells in new diabetes patients

NCT ID NCT06227221

Not yet recruiting Disease control Sponsor: Second Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether the cancer drug sorafenib can help people newly diagnosed with type 1 diabetes keep making their own insulin. Ten adults aged 18-60 will receive either sorafenib or a placebo daily, along with their usual insulin. The study measures changes in insulin production over time to see if the drug slows the loss of beta cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sorafenib (a cancer drug) taken as a daily pill
What this could lead to: If it works, this could point toward a way to preserve the body's own insulin production in people newly diagnosed with type 1 diabetes, potentially reducing the amount of insulin they need.
What could go wrong: This is a very small, early-phase trial with only 10 people, so results may not apply broadly. Sorafenib is a cancer drug with known side effects, and it is not yet clear if it will help diabetes or cause harm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

More trials for these conditions

Other studies related to the condition(s) this trial covers.